WO2004046317A3 - Products and processes for modulating peptide-peptide binding domain interactions - Google Patents

Products and processes for modulating peptide-peptide binding domain interactions Download PDF

Info

Publication number
WO2004046317A3
WO2004046317A3 PCT/US2003/036392 US0336392W WO2004046317A3 WO 2004046317 A3 WO2004046317 A3 WO 2004046317A3 US 0336392 W US0336392 W US 0336392W WO 2004046317 A3 WO2004046317 A3 WO 2004046317A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
products
processes
binding domain
modulating
Prior art date
Application number
PCT/US2003/036392
Other languages
French (fr)
Other versions
WO2004046317A2 (en
Inventor
Michael B Yaffe
Andrew E H Elia
Peter Rellos
Lewis C Cantley
Stephen J Smerdon
Isaac Manke
Original Assignee
Massachusetts Institue Of Tech
Michael B Yaffe
Andrew E H Elia
Peter Rellos
Lewis C Cantley
Stephen J Smerdon
Isaac Manke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institue Of Tech, Michael B Yaffe, Andrew E H Elia, Peter Rellos, Lewis C Cantley, Stephen J Smerdon, Isaac Manke filed Critical Massachusetts Institue Of Tech
Priority to JP2004570398A priority Critical patent/JP2007525143A/en
Priority to EP03783468A priority patent/EP1576128A4/en
Priority to CA002506246A priority patent/CA2506246A1/en
Priority to AU2003290883A priority patent/AU2003290883A1/en
Publication of WO2004046317A2 publication Critical patent/WO2004046317A2/en
Publication of WO2004046317A3 publication Critical patent/WO2004046317A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to therapeutic compounds and methods of use of these therapeutic compounds for treating cellular proliferative disorders. The invention also provides three-dimensional structures of a Polo-like kinase and methods for designing or selecting small molecule inhibitors using these structures, and the therapeutic use of such compounds. The invention also includes a method for identifying novel phosphopeptide-binding domains.
PCT/US2003/036392 2002-11-14 2003-11-14 Products and processes for modulating peptide-peptide binding domain interactions WO2004046317A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004570398A JP2007525143A (en) 2002-11-14 2003-11-14 Products and methods for modulating peptide-peptide binding domain interactions
EP03783468A EP1576128A4 (en) 2002-11-14 2003-11-14 Products and processes for modulating peptide-peptide binding domain interactions
CA002506246A CA2506246A1 (en) 2002-11-14 2003-11-14 Products and processes for modulating peptide-peptide binding domain interactions
AU2003290883A AU2003290883A1 (en) 2002-11-14 2003-11-14 Products and processes for modulating peptide-peptide binding domain interactions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US42613202P 2002-11-14 2002-11-14
US60/426,132 2002-11-14
US48564103P 2003-07-08 2003-07-08
US60/485,641 2003-07-08
US48789903P 2003-07-17 2003-07-17
US60/487,899 2003-07-17

Publications (2)

Publication Number Publication Date
WO2004046317A2 WO2004046317A2 (en) 2004-06-03
WO2004046317A3 true WO2004046317A3 (en) 2006-10-05

Family

ID=32329846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036392 WO2004046317A2 (en) 2002-11-14 2003-11-14 Products and processes for modulating peptide-peptide binding domain interactions

Country Status (6)

Country Link
US (3) US20050196808A1 (en)
EP (1) EP1576128A4 (en)
JP (1) JP2007525143A (en)
AU (1) AU2003290883A1 (en)
CA (1) CA2506246A1 (en)
WO (1) WO2004046317A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196808A1 (en) * 2002-11-14 2005-09-08 Yaffe Michael B. Products and processes for modulating peptide-peptide binding domain interactions
US20060052951A1 (en) * 2004-05-07 2006-03-09 Yaffe Michael B Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1
AU2005304638A1 (en) * 2004-11-12 2006-05-18 Massachusetts Institute Of Technology Methods and compositions for treating cellular proliferative diseases
US8440610B2 (en) * 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
JP4827444B2 (en) * 2005-06-24 2011-11-30 財団法人高輝度光科学研究センター A method for experimentally determining electrostatic potential by MEM structural analysis of X-ray diffraction data of crystalline materials
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
EP1892528A1 (en) * 2006-08-25 2008-02-27 Institut Pasteur Use of a modulating agent that interacts with the pbd of plk proteins for modulating ifn induction
SG172229A1 (en) 2008-12-18 2011-07-28 Hoffmann La Roche Thiazolyl-benzimidazoles
WO2010132869A2 (en) * 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
US9175357B2 (en) * 2011-02-04 2015-11-03 University Of South Carolina Fragment ligated inhibitors selective for the polo box domain of PLK1
WO2013177593A2 (en) 2012-05-25 2013-11-28 Phosimmune, Inc. Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
CN113316638A (en) 2018-11-20 2021-08-27 诺迪勒思生物科技公司 Design and selection of affinity reagents
CN111116374B (en) * 2019-12-04 2020-12-15 北京理工大学 Method for synthesizing pi-pi bond eutectic by aminoglutethimide and 2-nitrobenzoic acid
WO2024071401A1 (en) * 2022-09-29 2024-04-04 公益財団法人がん研究会 Drug screening method based on drug discovery concept of cancer cell proliferation inhibition induced by disruption of chromosome regulation due to plk1 kinase activation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532167A (en) * 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
US6358738B1 (en) * 1998-05-13 2002-03-19 The President And Fellows Of Harvard College Polo box therapeutic compositions, methods, and uses therefor
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
US20050085626A1 (en) * 2002-02-15 2005-04-21 Mount Sinai Hospital Polo domain structure
EP1375517A1 (en) * 2002-06-21 2004-01-02 Smithkline Beecham Corporation Structure of a glucocorticoid receptor ligand binding domain comprising an expanded binding pocket and methods employing same
US20050196808A1 (en) * 2002-11-14 2005-09-08 Yaffe Michael B. Products and processes for modulating peptide-peptide binding domain interactions
GB0326396D0 (en) * 2003-11-12 2003-12-17 Cyclacel Ltd Method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELIA A.E.H. ET AL.: "The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Piks by the Polo-Box Domain", CELL, vol. 115, 3 October 2003 (2003-10-03), pages 83 - 95, XP002328181 *
LEUNG G.C. ET AL.: "The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization", NAT. STRUCT. BIOL., vol. 9, no. 10, October 2002 (2002-10-01), pages 719 - 724, XP002401335 *
See also references of EP1576128A4 *

Also Published As

Publication number Publication date
US20050196808A1 (en) 2005-09-08
AU2003290883A8 (en) 2004-06-15
WO2004046317A2 (en) 2004-06-03
US20110104713A1 (en) 2011-05-05
EP1576128A4 (en) 2008-02-13
CA2506246A1 (en) 2004-06-03
EP1576128A2 (en) 2005-09-21
AU2003290883A1 (en) 2004-06-15
US20100030543A1 (en) 2010-02-04
JP2007525143A (en) 2007-09-06

Similar Documents

Publication Publication Date Title
WO2004046317A3 (en) Products and processes for modulating peptide-peptide binding domain interactions
WO2005048948A3 (en) Urea derivatives as kinase modulators
NO20032229L (en) Methods for treating p38kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
WO2003062236A8 (en) 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
WO2005012241A3 (en) p-38 KINASE INHIBITORS
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
BRPI0508036A (en) fused pyrazole derivatives
WO2007079164A3 (en) Protein kinase inhibitors
WO2004009776A3 (en) TREATMENT OF TNFα RELATED DISORDERS
WO2003082208A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
NO20085373L (en) P38 inhibitors, their preparation and use
MXPA06010904A (en) Tricyclic pyrazole kinase inhibitors.
NO20045451L (en) N-substituted tricyclic 3-aminopyrazoles as PDGF receptor inhibitors
ZA200702645B (en) Diaminotriazole compounds useful as protein kinase inhibitors
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
WO2007022241A3 (en) Novel high affinity quinoline-based kinase ligands
WO2005052147A3 (en) Method of screening for a modulator of cdk4
WO2004043379A3 (en) Chemical compounds
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2007050673A3 (en) Cyclin dependent kinase inhibitors
WO2007033374A3 (en) Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
WO2001028493A3 (en) Small molecule inhibitors of necrosis
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2004083376A3 (en) Modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2506246

Country of ref document: CA

Ref document number: 2004570398

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003783468

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003783468

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)